BIC22 takeaways
20/09/22 -"During BIC22, Roche confirmed the solid (recovery) momentum in Core Pharmas, along with ample support from less severe biosimilar headwinds and COVID-19 business’s moderation, confidence with ..."
Pages
67
Language
English
Published on
20/09/22
You may also be interested by these reports :
22/07/26
Lonza published its 1H results, with a strong operating performance but a mixed revenue outcome. The group grew by +16% (CER) YoY, with strong FX ...
21/07/26
The Q2 sales growth was supported by a healthy showing across both segments. The management now expects full-year growth to be at the upper end of ...
21/07/26
The Q2 results exceeded expectations, aided by the strong performance of cancer and neuroscience medicines, healthy growth in immunology offerings, ...
20/07/26
Bachem (ADD; Switzerland) is a peptide and oligonucleotide manufacturer, regarded as the most reliable partner in western economies as one of the few ...